Vimarsana
Biggest News Aggregation in the World

Page 4 - Proffered Paper News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Proffered Paper. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Proffered Paper Today - Breaking & Trending Today

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022 - Vimarsana News

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

– DCC-3116 Was Well-tolerated with No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events Observed – – Pharmacokinetic and Pharmacodynamic Data Across all Doses... | September 10, 2022

SpringWorks Therapeutics Announces Data from Phase 3 DeFi - Vimarsana News

SpringWorks Therapeutics Announces Data from Phase 3 DeFi

– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – –...

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022 - Vimarsana News

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma - Vimarsana News

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd: New data from the phase II CITYSCAPE trial show encouraging results with Roche's novel anti-TIGIT tiragolumab plus Tecentriq - Vimarsana News

F. Hoffmann-La Roche Ltd: New data from the phase II CITYSCAPE trial show encouraging results with Roche's novel anti-TIGIT tiragolumab plus Tecentriq

After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free